Led · Series C · Jul 2026

Endo Tools Therapeutics develops the endomina® platform, a triangulation and suturing system that can be affixed to standard endoscopes to enable suturing through a natural orifice and can be assembled on the endoscope inside the stomach. The platform includes suturing units and a recently FDA-cleared next-generation product, the endomina® EZFuse system, which features a single-movement suturing mechanism intended to streamline workflow and speed procedures. ETT positions the system to expand minimally invasive treatment options for patients with Class I and II obesity and to offer an alternative or complement to chronic GLP-1 therapy. In Europe and select Middle East countries the devices are approved for endoscopic gastroplasty, with over 1,500 procedures performed, while in the U.S. the devices are cleared for placement of sutures and approximation of soft tissue in the gastrointestinal tract. The company states its mission is to expand the range of gastrointestinal procedures possible with standard gastroscopes, aiming to reduce complications, shorten hospital stays, and improve patient comfort.

Participated · Series B · May 2026

Led by CEO Corey Tyree and based in Knoxville, TN, Trillium Renewable Chemicals has developed proprietary thermochemical technology to convert plant-based feedstocks such as glycerol into valuable intermediates including acrylonitrile and acetonitrile. These intermediates serve as inputs for ABS plastics, carbon fiber, acrylic fiber, nitrile butadiene rubber, acrylamide and specialty amines. The company plans to advance engineering and development of its first commercial-scale manufacturing plant using proceeds from its recent financing. Financially, Trillium has completed a $10.6M Series A and received a $2.5M non-dilutive award from the U.S. Department of Energy prior to this $13M Series B. The current raise is positioned to support scale-up from pilot to commercial production.

Led · Series A · Apr 2026

Rocsys builds hands-free charging and depot service solutions for electric and autonomous vehicle fleets, combining soft robotics, AI-driven computer vision and motion intelligence. Its newly announced M1 is an overhead rail-mounted, multi-bay charging system that can serve up to 10 bays from a single system and is interoperable across EVs, chargers and connector types. The M1 is currently in pilot deployment with large-scale rollout planned across North America and Europe in 2027, and the company says it can deliver up to a 75% productivity increase in depot operations and up to $1.7 million in annual savings at scale. Rocsys reports a 99.9%+ plug-in success rate in live environments and cites more than six years of real-world data and edge-case training underpinning its performance. The company's technology portfolio is supported by 130+ granted patents and pending applications and is already used in demanding environments such as ports. Financially, Rocsys has raised a total of $56M to date following the $13M Series A extension announced with participation from strategic investors including Capricorn Partners and Scania Invest.

Led · Seed · Feb 2026

Oska Health offers an AI-supported coaching platform that pairs certified health coaches with digital therapy tools to deliver continuous care for high-risk, multimorbid patients suffering from chronic kidney disease, diabetes, hypertension, and other long-term conditions. Through video calls, chat, and a dedicated app, coaches translate physicians’ recommendations into day-to-day actions, aiming to boost medication adherence, strengthen health literacy, and lower avoidable hospitalisations. The company’s proprietary AI augments care teams by triaging patient needs and reducing administrative workload, making personalised chronic-care support scalable. Operating for more than three years, Oska Health has demonstrated its ability to keep patients engaged between medical appointments. The newly raised capital will fund further expansion of its AI infrastructure and broaden access to its hybrid care model across Europe. Financial details beyond the recent seed round have not been disclosed.

Led · Equity · Feb 2026

Xyall BV is a molecular pathology technology company focused on automating the labor-intensive step of tissue dissection prior to PCR and next-generation sequencing analyses. Its flagship product, the Tissector TableTop, integrates high-resolution slide imaging, precise image registration, workflow software, and robotics to deliver fully automated, contamination-free tissue selection. Introduced in 2023, the system is already installed in more than 15 Tier-1 commercial, academic, pharmaceutical, and research labs, including sites in the United States. Customers adopt the platform to cope with staffing shortages and the demand for faster, more precise oncology diagnostics. By bridging morphological assessment and molecular diagnostics, Xyall positions itself as a critical enabler of personalized medicine. The company plans to use new capital to accelerate its global rollout and deepen penetration of both research and clinical laboratories. Its recent €7.6 million raise strengthens its balance sheet for these expansion efforts.